Notes on a classic theorem of Erdős and Grünwald

J. Szabados

DOI: https://doi.org/10.1016/j.jat.2011.02.008

IF: 0.993

2011-05-01

Journal of Approximation Theory

Abstract:

What problem does this paper attempt to address?

Case report: Bullous pemphigoid arising in a patient with scleroderma and multiple sclerosis

Francesco Moro,Feliciana Mariotti,Anna Pira,Naomi De Luca,Biagio Didona,Gianluca Pagnanelli,Giovanni Di Zenzo

DOI: https://doi.org/10.3389/fmed.2022.1055045

2022-12-08

Abstract:Background: Bullous pemphigoid (BP) is the most common autoimmune-blistering disease, clinically characterized by erythematous urticarial plaques, blisters, and intense pruritus, induced by autoantibodies against two proteins of the dermo-epidermal junction, BP180 and BP230. A large number of autoimmune diseases are reported in the literature as BP comorbidities, such as multiple sclerosis, but only a few cases are in association with scleroderma and none in association with both. Case presentation: We present the case of a 68-year-old woman affected by multiple sclerosis and scleroderma who developed severe bullous pemphigoid with a bullous pemphigoid disease area index of 60 and high titers of anti-BP180 and anti-BP230 autoantibodies by enzyme-linked immunosorbent assays. After 2 months of therapy with both intravenous and oral corticosteroids, the active lesions of bullous pemphigoid were remitted with no relapse. Conclusion: Autoimmune diseases affecting the skin or organs where BP180 and BP230 are present could trigger an immune response to these antigens through an epitope-spreading phenomenon and, over the years, induce bullous pemphigoid onset.
Case report: Bullous pemphigoid combined with Sjögren's syndrome complicated by central nervous system infection

Xing-Yue Chen,Jun Chen,Kun-Lan Long,Peng Ding,Rong Li,Li-Jia Zhi

DOI: https://doi.org/10.3389/fimmu.2024.1419054

2024-09-10

Abstract:Background: Bullous pemphigoid (BP) is the most common autoimmune blistering skin disease in humans, characterized by tense blisters, erosions, urticarial lesions, and itching on normal or erythematous skin. Many autoimmune diseases are considered comorbidities of BP, but clinical case reports of BP complicated by Sjögren's syndrome are very scarce. Furthermore, cases of central nervous system infection secondary to both autoimmune diseases are even rarer. Case presentation: We report a 74-year-old woman diagnosed with bullous pemphigoid, who showed relief of active lesions after treatment with methylprednisolone and dupilumab injections. However, she was admitted for pulmonary infection during which she was diagnosed with Sjögren's syndrome (SS). Subsequently, the patient developed altered consciousness, indicating a central nervous system infection. Adjustment of steroid dosage and aggressive antimicrobial therapy led to alleviation of symptoms. Conclusion: The coexistence of autoimmune subepidermal blistering diseases and SS is rare. The role of SS in the pathogenesis of skin lesions is unclear, and the relationship between these blistering diseases and SS remains elusive. Further research is needed to determine whether there are common pathological mechanisms between the two conditions.
To Cut is to Cure: The Surgeon's Role in Improving Value

J. Jopling,Clifford C. Sheckter,B. James

DOI: https://doi.org/10.1097/SLA.0000000000002596

IF: 13.787

2017-11-01

Annals of Surgery

Abstract:SURGEONS WILL INCREASINGLY BEAR FINANCIAL RISK WITH NEW PAYMENT MODELSValue-based reimbursement is supplanting traditional fee-for-service payment. Forward thinking payers, providers, and patients are redesigning care delivery to maximize patient experience and population-level health at an affordab
Wound keratins in the regenerating epidermis of lizard suggest that the wound reaction is similar in the tail and limb.

L. Alibardi,M. Toni

DOI: https://doi.org/10.1002/JEZ.A.213

2005-10-01

Journal of Experimental Zoology Part A Comparative Experimental Biology

Abstract:The keratin cytoskeleton of the wound epidermis of lizard limb (which does not regenerate) and tail (which regenerates) hase been studied by qualitative ultrastructural, immunocytochemical, and immunoblotting methods. The process of re-epithelialization is much shorter in the tail than in the limb. In the latter, a massive tissue destruction of bones, and the shrinkage of the old skin over the stump surface, delay wound closure, maintain inflammation, reduce blastemal cell population, resulting in inhibition of regeneration. The expression of special wound keratins found in the newt epidermis (W6) or mammalian epidermis (K6, K16, and K17) is present in the epidermis of both tail and limb of the lizard. These keratins are not immunolocalized in the migrating epithelium or normal (resting) epidermis but only after it has formed the thick wound epithelium, made of lacunar cells. The latter are proliferating keratinocytes produced during the cyclical renewal or regeneration of lizard epidermis. W6-immunolabeled proteic bands mainly at 45-47 kDa are detected by immunoblotting in normal, regenerating, and scarring epidermis of the tail and limb. Immunolabeled proteic bands at 52, 62-67 kDa (with K6), at 44-47, 60, 65 kDa (with K16), and at 44-47 kDa (with K17) were detected in normal and regenerating epidermis. It is suggested that: (1) these keratins constitute normal epidermis, especially where the lacunar layer is still differentiating; (2) the wound epidermis is similar in the limb and tail in terms of morphology and keratin content; (3) the W6 antigen is similar to that of the newt, and is associated with tonofilaments; (4) lizard K6 and K17 have molecular weights similar to mammalian keratins; (5) K16 shows some isoforms or degradative products with different molecular weight from those of mammals; (6) K17 increases in wound keratinocytes and localizes over sparse filaments or small bundles of short filaments, not over tonofilaments joined to desmosomes; and (7) failure of limb regeneration in lizards may not depend on the wound reaction of keratinocytes.
Case Report: Coexistence of bullous pemphigoid and psoriasis: Therapeutic challenge and IL17A-targeted parallel treatment strategy

Kossara Drenovska,Elia Valeva,Martin Shahid,Snejina Vassileva

DOI: https://doi.org/10.3389/fmed.2023.1148660

IF: 3.9

2023-04-03

Frontiers in Medicine

Abstract:Autoimmune blistering diseases of the skin have all been reported in patients with psoriasis, bullous pemphigoid (BP) being the most frequently observed. The pathophysiologic triggers for BP in psoriatic patients are unclear. Recent observational studies have suggested that chronic psoriatic inflammation may cause pathological changes to the basement membrane zone, thus inducing autoimmunity against BP antigens through cross reactivity and “epitope spreading.” The coexistence of BP and psoriasis poses challenging therapeutic dilemmas related to the incompatibility of their standard treatments. Considering the probable common immunologic mechanisms in the pathogenesis of these inflammatory skin disorders, a suitable treatment regimen should be applied for their parallel control. We report three patients, who developed BP in the course of preceding long-lasting psoriasis. Secukinumab was administered as first-line treatment with promising therapeutic effect for both skin disorders and long-term disease control in two of the cases. In the third case, parallel disease control was initially achieved with methotrexate. A few years later, secukinumab was used for the treatment of a relapse of both dermatoses but worsening of BP was observed and methotrexate was reintroduced. Our experience on the therapeutic potential of secukinumab in BP is supported by the data in the literature. Recently, it was demonstrated that the proinflammatory cytokine IL17A has a functional role in the process of skin inflammation in BP, similarly to psoriasis. IL17A inhibition has emerged as a promising therapeutic strategy in patients with extensive or refractory BP but paradoxical development of BP after secukinumab treatment for psoriasis has also been described. This controversy emphasizes the need for further investigation into the development of optimal treatment strategies and recommendations.

medicine, general & internal
Case Report: The many faces of bullous pemphigoid

Laura Rechtien,Lukas Sollfrank,Yannick Foerster,Carola Berking,Michael Sticherling

DOI: https://doi.org/10.3389/fimmu.2023.1272742

2023-10-12

Abstract:The pemphigoid group comprises a number of bullous skin diseases with autoantibodies against different constituents of the basement membrane zone that result in subepidermal detachment and clinically characteristic tense blisters, erosions, urticarial erythema, and itching. Apart from the most frequent type of bullous pemphigoid with antibodies against BP180, which is found predominantly in elderly patients, the disease may present at other ages and different pathogenic conditions. Here, four cases are presented of young age (3 months and 25, 34, and 46 years) and in association with vaccination, pregnancy, or metastatic cancer. Though anti-BP180 was found in all cases, a different pathogenic background may be found in any of them, resulting in characteristic clinical manifestation, yet demanding specifically adapted therapeutic approaches.
Immunosuppressive Kaposi's Sarcoma with Bullous Pemphigoid Associated with Hepatitis B Virus Infection.

Ting Xiao,Hong-Guang Lu,Guishan Jin,Jian Wu,Zhihua Wang,Hongen Xu,Xinghua Gao,Hong‐Duo Chen

DOI: https://doi.org/10.1684/ejd.2009.0698

2009-01-01

Abstract:Auteur(s) : Ting Xiao1, Hong-Guang Lu2, Guang-Yu Jin1, Jian Wu1, Zhi-Hua Wang1, Hong-Hui Xu1, Xing-Hua Gao1, Hong-Duo Chen1 1Department of Dermatology, No. 1 Hospital of China Medical University, 155 North Nanjing Street, Shenyang 110001, China 2Department of Dermatology, Affiliated Hospital of Guiyang Medical Collage, Guiyang, China Bullous pemphigoid (BP) is an autoimmune blistering disease commonly seen in the elderly. There have been few cases of immunosuppressive [...]
Effects of a candidate antifouling compound (medetomidine) on pheromone induced mate search in the amphipod Corophium volutator.

Anna-Sara Krång,M. Dahlström

DOI: https://doi.org/10.1016/J.MARPOLBUL.2006.09.015

IF: 5.8

2006-12-01

Marine Pollution Bulletin

Abstract:
Deformities of the metacarpus and metatarsus in fallow deer (Dama dama L.).

D. Chapman,N. Chapman,L. Jeffcott

DOI: https://doi.org/10.1016/0021-9975(84)90010-0

IF: 1.083

Journal of Comparative Pathology

Abstract:
Imported heterosexual HIV infection in London

S. Mitchell,B. Band,C. Bradbeer,D. Barlow,A. Noone,V. Gilbart,B. Evans

DOI: https://doi.org/10.1016/0140-6736(91)93317-3

IF: 202.731

1991-06-29

The Lancet

Abstract:
Advancements in Bullous Pemphigoid Treatment: A Comprehensive Pipeline Update

Meropi Karakioulaki,Kilian Eyerich,Aikaterini Patsatsi

DOI: https://doi.org/10.1007/s40257-023-00832-1

Abstract:Bullous pemphigoid (BP) is a common autoimmune bullous disease affecting mainly the elderly, with rising incidence due to increased life expectancy. This disease is characterized by tense bullous lesions on normal or erythematous skin, accompanied by pruritus. BP pathogenesis involves autoantibodies against hemidesmosomal proteins BP180 and BP230, leading to detachment at the dermo-epidermal junction as well as blister formation. BP is associated with coexisting comorbidities and drug exposure, and its management often requires high doses or chronic use of systemic glucocorticoids, posing risks of adverse effects. This review focuses on novel treatment options for BP, exploring therapies targeting different immune pathways. Rituximab, a CD20 monoclonal antibody, depletes B-lymphocytes and has shown efficacy in severe cases. Dupilumab, targeting interleukin (IL)-4 receptor α and thus blocking IL-4 and IL-13, downregulates type 2 helper (Th2) responses and has demonstrated promising results. Targeting eosinophil-related molecules using bertilimumab and AKST4290 has yielded positive results in clinical trials. Omalizumab, an immunoglobulin (Ig) E antibody, can reduce disease severity and allows corticosteroid tapering in a number of cases. Complement inhibitors such as nomacopan and avdoralimab are being investigated. IL-17 and IL-23 inhibitors such as secukinumab and tildrakizumab have shown potential in a limited number of case reports. Neonatal Fc receptor antagonists such as efgartigimod are under investigation. Additionally, topical therapies and Janus kinase inhibitors are being explored as potential treatments for BP. These novel therapies offer promising alternatives for managing BP, with potential to improve outcomes and reduce high cumulative doses of systemic corticosteroids and related toxicities. Further research, including controlled clinical trials, is needed to establish their efficacy, safety, and optimal dosing regimens for BP management.
Research into purchasing health care : time to face the challenge

T. Marshall

Abstract:
A case report of steroid-refractory bullous pemphigoid induced by immune checkpoint inhibitor therapy

Shasha Guan,Linlin Zhang,Junyan Zhang,Wenjing Song,Diansheng Zhong

DOI: https://doi.org/10.3389/fimmu.2022.1068978

IF: 7.3

2023-01-05

Frontiers in Immunology

Abstract:The widespread use of immune checkpoint inhibitors in several malignancies has revealed new immune-related adverse events. Bullous pemphigoid (BP) is an antibody-driven autoimmune disease characterized by skin inflammation and fluid-filled bullae. Herein, a 69-year-old man with lung squamous cell carcinoma developed multiple vesicles and tense bullae 3 weeks after the initiation of a programmed death-1 (PD-1) inhibitor, pembrolizumab, and chemotherapy. Biopsy revealed a subepidermal bulla with lymphocytic and eosinophil infiltration, and immunohistochemical studies predominantly showed CD4 + cells, a few CD8 + cells, and the occasional CD20 + lymphocyte. The serum anti-BP180 antibody level, as well as the interleukin-6 and interleukin-10 levels, were elevated compared to the lower levels of tumor necrosis factor-α. Eosinophil levels were high and consistent with the development of blisters. A diagnosis of BP associated with PD-1 inhibitor therapy was made, and the Common Terminology Criteria for Adverse Events classification was grade 3. Immunotherapy was permanently discontinued, and the patient's bullous lesions failed to react to high-dose systemic corticosteroids combined with minocycline and niacinamide. Intermittent blister recurrence occurred in 2 months, eventually improving with the administration of two courses of intravenous immunoglobulin. At 5 weeks of follow-up, the patient's tumor was reduced on a computed tomographic scan. Despite stable BP treatment, however, he repeatedly developed complications due to the complexity of his underlying disease and could not be treated with anti-tumor therapy. Early recognition and management of serious immune-related bullous dermatologic toxicity are essential for patient safety.

immunology
A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors

Adriana T Lopez,Trisha Khanna,Nina Antonov,Claire Audrey-Bayan,Larisa Geskin

DOI: https://doi.org/10.1111/ijd.13984

Abstract:Background: Dermatologic toxicity represents a substantial portion of all immune-related adverse events (irAEs) associated with PD-1/PD-L1 inhibitors. Bullous pemphigoid (BP) is a rare cutaneous side effect of these medications, which can initially be clinically indistinguishable from other, low-grade cutaneous toxicity. Objective: To better characterize the clinical features of BP associated with PD-1/PD-L1 inhibitors, evaluate the efficacy of various treatment regimens, determine the frequency of prodromal pruritus, and assess whether immunological diagnostic studies for BP are warranted in patients treated with checkpoint inhibitors who develop intractable pruritus. Methods: A comprehensive review of the English-language medical literature was performed using key terms. Papers published on any date and from all origins were considered. Fourteen publications, containing 21 patient cases, were selected independently by two reviewers and deemed relevant to the present publication. Results: Pruritus was a prominent feature of the majority (12/21) of cases and preceded or occurred concurrently with BP development. Bullae developed within 6-8 months of initiation of PD-1/PD-L1 inhibitors; however, a smaller subset of patients did not develop bullae for 1-1.5 years following initiation of therapy. Mean time to pruritus was similar for pembrolizumab and nivolumab at 19 and 21 weeks, respectively. Development of BP required discontinuation of immunotherapy in 76% (16/21) of cases. Conclusion: Prodromal or "non-bullous" variants of BP must be considered in patients treated with checkpoint inhibitors who develop protracted or worsening pruritus. Early diagnostic immunological evaluation of the skin may lead to improved patient outcomes by facilitating timely initiation of treatment and prevent disruptions in cancer therapy.
Atypical Presentation of Severe Bullous Pemphigoid: A Case Report

Tinotenda Sekeramayi,Sara Ruter

Abstract:Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disorder. Typically, patients will present with tense bullae and intense generalized pruritus with a skin biopsy demonstrating subepidermal split with eosinophils and a direct immunofluorescence highlighting autoantibodies against the basement membrane zone. Prognosis varies, and treatment involves an assessment of the severity of disease to determine whether to initiate topical or systemic immunosuppressive agents. We present an atypical presentation of BP that presented as a 3-to-4-week duration of pruritic small vesicular lesions in the upper chest, scabbed circular lesions along the upper extremity and pinnas of bilateral ear. Initially thought to be herpes zoster infection initially treated with valacyclovir for a week following a prior concern of a concomitant superficial skin infection with cephalexin and prednisone. With no clinical improvement, tissue biopsy was performed that confirmed bullous pemphigoid and treatment with steroid taper, doxycycline, and triamcinolone acetonide 0.1% cream was started. The aim of this case report is to present an atypical presentation of BP and to highlight maintaining a high index of suspicion of BP in patients presenting with disseminated significantly pruritic lesions.
Currently approved post-exposure rabies prophylaxis regimens.

H. Wilde,S. Wacharapluesadee,T. Hemachudha

DOI: https://doi.org/10.1016/j.tmaid.2012.03.004

IF: 20.441

2012-05-01

Travel Medicine and Infectious Disease

Abstract:
Bullous Pemphigoid Associated With the Use of Sacubitril/Valsartan: A Case Report and Literature Review

Daniel A Martin Arsanios,Lina M Gómez-Álvarez,Natalia Muñoz-Angulo,Claudia Montealegre,Elias Quintero Muñoz,Carlos Calderón-Vargas

DOI: https://doi.org/10.7759/cureus.53160

2024-01-29

Cureus

Abstract:Bullous pemphigoid (BP) is a complex autoimmune blistering disease with an increased incidence in the comorbid population, particularly among older adults. The occurrence of drug-induced BP is associated with an underlying genetic predisposition, triggering an enhanced immune response, the formation of autoantibodies, and alterations in antigenic properties within the basement membrane zone. With over 90 identified drugs capable of precipitating BP, we present the case of an 87-year-old woman with comorbidities who experienced a medication change from losartan to sacubitril/valsartan. Three months later, erythematous lesions appeared on her lower limbs, progressing to a generalized rash accompanied by itching. Over the following month, these lesions evolved into tense blisters with serous content and intense pain. Suspecting the medication switch to sacubitril/valsartan as the cause, the drug was discontinued, and immunomodulatory treatment was initiated, resulting in a notable improvement in the lesions.
Pathophysiology of Bullous Pemphigoid: Role of Type 2 Inflammation and Emerging Treatment Strategies (Narrative Review)

Victoria P. Werth,Dédée F. Murrell,Pascal Joly,Renata Heck,Jamie M. Orengo,Marius Ardeleanu,Verena Hultsch

DOI: https://doi.org/10.1007/s12325-024-02992-w

2024-11-11

Advances in Therapy

Abstract:Bullous pemphigoid (BP) is an autoimmune blistering disease that most often affects elderly individuals and has a significant negative impact on quality of life. The disease is characterized primarily by autoantibodies to hemidesmosomal proteins BP180 and/or BP230, and an inflammatory reaction with notable features of type 2 inflammation, including elevated serum IgE, increased numbers of eosinophils in lesions and peripheral blood, and elevated expression of type 2 cytokines and chemokines in skin lesions. In this review, we present what is known about BP pathophysiology, including the role of type 2 inflammation, and discuss how findings from studies of biologics targeting type 2 immune mediators have helped to clarify the biological mechanisms driving BP pathophysiology. Future studies of these targeted therapies and others in development will help to further elucidate the mechanisms underlying BP pathophysiology and potentially provide better treatment options for patients.

pharmacology & pharmacy,medicine, research & experimental
Autoreactive Peripheral Blood T Helper Cell Responses in Bullous Pemphigoid and Elderly Patients With Pruritic Disorders

Dario Didona,Luca Scarsella,Milad Fehresti,Farzan Solimani,Hazem A Juratli,Manuel Göbel,Stefan Mühlenbein,Lily Holiangu,Josquin Pieper,Vera Korff,Thomas Schmidt,Cassian Sitaru,Rüdiger Eming,Michael Hertl,Robert Pollmann

DOI: https://doi.org/10.3389/fimmu.2021.569287

2021-03-25

Abstract:Bullous pemphigoid (BP) is a prototypic autoimmune disorder of the elderly, characterized by serum IgG autoantibodies, namely anti-BP180 and anti-BP230, directed against components of the basal membrane zone that lead to sub-epidermal loss of adhesion. Pruritus may be indicative of a pre-clinical stage of BP, since a subset of these patients shows serum IgG autoantibodies against BP230 and/or BP180 while chronic pruritus is increasingly common in the elderly population and is associated with a variety of dermatoses. Clinical and experimental evidence further suggests that pruritus of the elderly may be linked to autoimmunity with loss of self-tolerance against cutaneous autoantigens. Thus, the objective of this study was to determine autoreactive T cell responses against BP180 in elderly patients in comparison to patients with BP. A total of 22 elderly patients with pruritic disorders, 34 patients with bullous or non-bullous BP and 34 age-matched healthy controls were included in this study. The level of anti-BP180 and anti-BP230 IgG serum autoantibodies, Bullous Pemphigoid Disease Area Index (BPDAI), and pruritus severity were assessed for all patients and controls. For characterization of the autoreactive T cell response, peripheral blood mononuclear cells were stimulated ex vivo with recombinant BP180 proteins (NH2- and COOH-terminal domains) and the frequencies of BP180-specific T cells producing interferon-γ, interleukin (IL)-5 or IL-17 were subsequently determined by ELISpot assay. Patients with BP showed a mixed Th1/Th2 response against BP180 while autoreactive Th1 cells were identified in a minor subset of elderly patients with pruritic disorders. Furthermore, our T cell characterization revealed that therapeutic application of topical clobetasol propionate ointment in BP patients significantly reduced peripheral blood BP180-specific T cells, along with clinically improved symptoms, strongly suggesting a systemic immunosuppressive effect of this treatment.
Malignancies in bullous pemphigoid: A controversial association

Riccardo Balestri,Michela Magnano,Michelangelo La Placa,Annalisa Patrizi,Luisa Angileri,Vera Tengattini,Federico Bardazzi

DOI: https://doi.org/10.1111/1346-8138.13079

Abstract:Bullous pemphigoid (BP) is an autoimmune subepidermal blistering disorder that has been reported to be associated with malignancies. Some authors described several cases of pemphigoid associated with malignancies (PAM); however, the evidence of this correlation still remains controversial. Several theories have been postulated to explain the relationship between malignant neoplasms and BP; the main theory suggests that antibodies directed against tumor-specific antigens of malignant cells may cross-react with antigens (like BP antigens) in the basement membrane zone leading to the formation of blisters. We performed an extensive review of the English published work focusing on the epidemiology, the pathogenetic theories and the clinical and histological aspects of the disease. We identified 40 cases of PAM: of these, seven cases were associated with hematological malignancies and 33 with solid tumors. Physicians should be aware of the existence of PAM and we suggest an oncological screening in early-onset pemphigoid, in patients with a former oncological history, in those with signs and symptoms that could be related to a neoplasm and in BP refractory to common immunosuppressive therapy.

Notes on a classic theorem of Erdős and Grünwald

Case report: Bullous pemphigoid arising in a patient with scleroderma and multiple sclerosis

Case report: Bullous pemphigoid combined with Sjögren's syndrome complicated by central nervous system infection

To Cut is to Cure: The Surgeon's Role in Improving Value

Wound keratins in the regenerating epidermis of lizard suggest that the wound reaction is similar in the tail and limb.

Case Report: Coexistence of bullous pemphigoid and psoriasis: Therapeutic challenge and IL17A-targeted parallel treatment strategy

Case Report: The many faces of bullous pemphigoid

Immunosuppressive Kaposi's Sarcoma with Bullous Pemphigoid Associated with Hepatitis B Virus Infection.

Effects of a candidate antifouling compound (medetomidine) on pheromone induced mate search in the amphipod Corophium volutator.

Deformities of the metacarpus and metatarsus in fallow deer (Dama dama L.).

Imported heterosexual HIV infection in London

Advancements in Bullous Pemphigoid Treatment: A Comprehensive Pipeline Update

Research into purchasing health care : time to face the challenge

A case report of steroid-refractory bullous pemphigoid induced by immune checkpoint inhibitor therapy

A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors

Atypical Presentation of Severe Bullous Pemphigoid: A Case Report

Currently approved post-exposure rabies prophylaxis regimens.

Bullous Pemphigoid Associated With the Use of Sacubitril/Valsartan: A Case Report and Literature Review

Pathophysiology of Bullous Pemphigoid: Role of Type 2 Inflammation and Emerging Treatment Strategies (Narrative Review)

Autoreactive Peripheral Blood T Helper Cell Responses in Bullous Pemphigoid and Elderly Patients With Pruritic Disorders

Malignancies in bullous pemphigoid: A controversial association